Kura Oncology’s fair value estimate has been adjusted from US$32.27 to US$31.08, a small move that still reflects detailed ...

The systemic lupus erythematosus (SLE) market continues to evolve toward biologic-driven care, with increasing treatment complexity, intensifying competition among advanced therapies, and a robust ...

Twenty-seven years ago today, a Broadway legend who also wrote a long list of hit songs died of cancer in Florida.

Greta Garbo was a silent film star during the golden era of Hollywood. She was ranked No. 5 on the American Film Institute’s ...

Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare ...

Unicycive Therapeutics, Inc. (UNCY) 25th Annual Needham Virtual Healthcare Conference April 15, 2026 3:45 PM EDTCompany ParticipantsShalabh Gupta - ...

Objective The multinational ERYTHRO ( NCT06046534) study investigated the experience of patients with moderate-to-severe SLE ...

Idorsia’s analyst story has shifted again, with a new CHF 5 price target sitting alongside an unchanged fair value estimate of CHF 4.5. This reset reflects a mix of confidence in the company’s assets ...

VB4-P5 - novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease • CALGARY, Alberta, April 13, 2026 (GLOBE NEWSWIRE) -- XORTX Therape ...

Investing.com -- Kura Oncology (NASDAQ:KURA) shares rose 9% Friday following the release of preliminary trial data showing its drug combination demonstrated activity in patients with clear cell renal ...

Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treat ...